Company Filing History:
Years Active: 2014
Title: Mark Law: Innovator in T-Cell Lymphoma Research
Introduction
Mark Law is an accomplished inventor based in Rochester, MN (US). He has made significant contributions to the field of medical research, particularly in the area of T-cell lymphomas. His innovative work has led to the development of methods aimed at reducing the expression of specific polypeptides associated with these conditions.
Latest Patents
Mark Law holds a patent for "Reducing IRF4, DUSP22, or FLJ43663 polypeptide expression." This patent relates to the activity of interferon regulatory factor 4 (IRF4) in T-cell lymphomas. The document outlines methods and materials involved in reducing the expression of an IRF4 polypeptide in T-cell lymphoma cells. It also identifies agents capable of reducing the expression of IRF4, DUSP22, or FLJ43663 polypeptides in T-cell lymphoma cells.
Career Highlights
Mark Law is affiliated with the Mayo Foundation for Medical Education and Research, where he continues to advance his research in the medical field. His work is crucial in understanding and potentially treating T-cell lymphomas, which can have significant implications for patient care.
Collaborations
Mark collaborates with notable colleagues, including Andrew L Feldman and Ahmet Dogan. These partnerships enhance the research efforts and contribute to the development of innovative solutions in the field of oncology.
Conclusion
Mark Law's contributions to T-cell lymphoma research through his patent and work at the Mayo Foundation for Medical Education and Research highlight his role as a key innovator in the medical field. His efforts are paving the way for advancements in treatment options for patients suffering from T-cell lymphomas.